The marketing and intelligence engine partners don't have in-house.

PAP is not a physician-access broker, not a KOL introduction service and not a sponsored-content shop. We are the content and intelligence engine most medical device, pharma and health-services companies either build slowly and expensively in-house — or outsource across five agencies who don't talk to each other and don't understand the clinical category.

Why this category, now

Pelvic health has moved from a quiet, fragmented clinical space into a commercial and regulatory priority. Four things are converging:

• Regulatory harmonization. EUDAMED modules going live in the EU, FDA post-market surveillance intensifying on implantable pelvic devices, Health Canada and ANVISA tightening cross-border requirements.
• Reimbursement expansion. Payer movement on pelvic-floor therapy, birth-injury prevention and perimenopause management — opening access windows for devices and services previously excluded.
• Category convergence. Wearables, digital therapeutics and connected devices entering pelvic health, expanding the addressable buyer set well beyond traditional medtech.
• Demographics. Prevalence of pelvic floor disorders in US women runs from 9.7% at ages 20–39 to 49.7% after 80 (Nygaard et al., JAMA 2008). The addressable population expands every year without a single new diagnosis code.

Organised around condition, not subspecialty

This is the structural decision everything else follows from. FPMRS in the United States alone is roughly 2,800 physicians — a critical audience, and far too narrow to define a commercial opportunity.

PAP covers the category the way patients actually experience it, across urogynecology, urology, minimally invasive gynecologic surgery, OB-GYN, colorectal care and pelvic-floor physical therapy — and reaches the clinicians and referring networks who see these patients, not just the subspecialists who operate on them.

What companies buy today, and where it breaks

Syndicated market research

Broad coverage across all of medtech, priced accordingly. Pelvic health appears as a chapter, not a practice. No patient audience, no physician relationship, and nothing you can publish.

Physician networks and panels

Reach into clinicians, with no editorial standard attached. The audience is rented, and nothing produced through it survives a compliance review on its own merits.

Consumer health publishers

Genuine patient scale, no category depth, no industry intelligence. General-health content, not a condition practice you can build a market-access argument on.

Agencies

Execution capacity without clinical category knowledge. Every claim gets verified by your own medical affairs team, which is where the cost and the delay actually sit.

Specialty societies

The highest clinical authority in the category — and structurally unable to act as a commercial content partner.

Each is a partial answer. None is a single provider with a patient audience, a cross-subspecialty physician audience, category intelligence, and a documented editorial standard that makes the output co-brandable. That combination is what PAP was built to be.

What partners engage us for

• Weekly market intelligence — a filtered, ranked view of what regulators, competitors, clinicians and payers are actually doing, before it moves the market. Delivered in Clinical, Industry and Global Markets editions.
• Strategic deep-dives — commissioned category, competitive and market-access analysis at consulting-grade depth, inside a subscription relationship rather than a six-month engagement.
• Localized awareness content — patient guides, physician education and social content produced to our editorial standard and co-branded for your region and language.
• Congress coverage — pre-reads, on-site reporting and post-event synthesis.
• Commissioned research — custom market intelligence on segments where public data is thin.
• Named recognition — launch partners receive named platform recognition, not a sponsorship placement or a logo insertion.

What we are not

Clarity on this matters, because it's what makes the rest usable.

• We don't sell physician access.
• We don't run sponsored briefings with predetermined conclusions.
• We don't broker KOL introductions.
• We don't accept paid placement inside our editorial products.

Every partner relationship is disclosed. Every claim in a co-branded piece is verified against professional-society sources. Our full process — source tiering, claim verification, the red-team pass, versioned publication — is public in our Editorial Standard.

How this starts

With a conversation, not a checkout. Industry work is scoped to the question, so there is no price on this page and there shouldn't be.